Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome

Pediatric Blood and Cancer

Volumn 51, Issue 3, 2008, Pages 418-420

  Smith, Angela R ^a   Hennessy, Jane M ^b   Heisel Kurth, Margaret A ^b   Nelson, Stephen C ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

Author keywords

Avastin; Bevacizumab; Bony toxicity; CAT syndrome

Indexed keywords

BEVACIZUMAB; CATECHOLAMINE; HEMOGLOBIN; STEROID; VINCRISTINE;

ANAMNESIS; ARTICLE; BLOOD CELL COUNT; BONE GROWTH; BONE LESION; BONE METABOLISM; CASE REPORT; CATECHOLAMINE URINE LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOVISCERAL ANGIOMATOSIS; EPIPHYSIS PLATE; GASTROINTESTINAL HEMORRHAGE; HEMANGIOMATOSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INFANT; LABORATORY TEST; METAPHYSIS; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN BIOPSY; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANGIOGENESIS INHIBITORS; ANGIOMATOSIS; ANTIBODIES, MONOCLONAL; BONE DISEASES; HUMANS; INFANT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 48249130817     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21597     Document Type: Article

References (9)

1. Prasad V, Fishman SJ, Mulliken JB, et al. Cutaneovisceral angiomatosis with thrombocytopenia. Pediatr Dev Pathol 2005;8:407-419.
2. North PE, Kahn T, Cordisco MR, et al. Multifocal lymphangioendotheliomatosis with thrombocytopenia: A newly recognized clinicopathological entity. Arch Dermatol 2004;140:599-606.
3. Middleton G, Lapka DV. Bevacizumab (Avastin). Clin J Oncol Nurs 2004;8:666-669.
4. Zakarija A, Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol 2005;17:578-583.
5. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: Case report and literature review. Am J Kidney Dis 2007;49:e23-e29.
6. Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J. Clin Oncol 2008;26:399-405.
7. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611.
8. Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623-628.
9. Ryan AM, Eppler DB, Hagler KE, et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999;27:78-36.